相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effects of variations in duodenal glucose load on glycaemic, insulin, and incretin responses in type 2 diabetes
J. Ma et al.
DIABETIC MEDICINE (2012)
Rapid Tachyphylaxis of the Glucagon-Like Peptide 1-Induced Deceleration of Gastric Emptying in Humans
Michael A. Nauck et al.
DIABETES (2011)
Physiological and Pharmacological Mechanisms through which the DPP-4 Inhibitor Sitagliptin Regulates Glycemia in Mice
Aurelie Waget et al.
ENDOCRINOLOGY (2011)
Endogenous GLP-1 Regulates Postprandial Glycemia in Humans: Relative Contributions of Insulin, Glucagon, and Gastric Emptying
Mathias Nicolaus et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Inhibition of DPP-4 with Vildagliptin Improved Insulin Secretion in Response to Oral as well as Isoglycemic Intravenous Glucose without Numerically Changing the Incretin Effect in Patients with Type 2 Diabetes
Irfan Vardarli et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Involvement of endogenous glucagon-like peptide-1 in regulation of gastric motility and pancreatic endocrine secretion
Anne-Barbara Witte et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2011)
Effect of Endogenous GLP-1 on Insulin Secretion in Type 2 Diabetes
Marzieh Salehi et al.
DIABETES (2010)
Endogenous Glucagon-Like Peptide-1 Slows Gastric Emptying in Healthy Subjects, Attenuating Postprandial Glycemia
Adam M. Deane et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Differential incretin effects of GIP and GLP-1 on gastric emptying, appetite, and insulin-glucose homeostasis
T. Edholm et al.
NEUROGASTROENTEROLOGY AND MOTILITY (2010)
Novel therapeutics for type 2 diabetes: Incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors
E. J. Verspohl
PHARMACOLOGY & THERAPEUTICS (2009)
Differential effect of PYY1-36 and PYY3-36 on gastric emptying in man
A. -B. Witte et al.
REGULATORY PEPTIDES (2009)
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
Daniel J. Drucker et al.
LANCET (2008)
Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes
Helle Linnebjerg et al.
REGULATORY PEPTIDES (2008)
The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion
Andrea El-Ouaghlidi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors
Carolyn F. Deacon
DIABETES OBESITY & METABOLISM (2007)
Load-dependent effects of duodenal glucose on glycemia, gastrointestinal hormones, antropyloroduodenal motility, and energy intake in healthy men
Amelia N. Pilichiewicz et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2007)
Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes
Adrian Vella et al.
DIABETES (2007)
Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes
Gary A. Herman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Effects of fat on gastric emptying of and the glycemic, insulin, and incretin responses to a carbohydrate meal in type 2 diabetes
Diana Gentilcore et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: Relationships with postprandial glycemic and insulinemic responses
TJ Little et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans
J Schirra et al.
GUT (2006)
Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteers
AJ Bergman et al.
CLINICAL THERAPEUTICS (2006)
Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses
GA Herman et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes
A Mari et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects
JJ Meier et al.
DIABETES (2005)
Evaluation of interactions between CCK and GLP-1 in their effects on appetite, energy intake, and antropyloroduodenal motility in healthy men
IM Brennan et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2005)
Glucagon-like peptide-1 secretion is influenced by perfusate glucose concentration and by a feedback mechanism involving somatostatin in isolated perfused porcine ileum
L Hansen et al.
REGULATORY PEPTIDES (2004)
Gastric inhibitory polypeptide does not inhibit gastric emptying in humans
JJ Meier et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2004)
Effects of lipase inhibition on gastric emptying of, and on the glycaemic, insulin and cardiovascular responses to, a high-fat/carbohydrate meal in type 2 diabetes
D O'Donovan et al.
DIABETOLOGIA (2004)
Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes
MA Nauck et al.
DIABETES (2004)
Effect of variations in small intestinal glucose delivery on plasma glucose, insulin, and incretin hormones in healthy subjects and type 2 diabetes
DG O'Donovan et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Effect of lipase inhibition on gastric emptying of, and the glycemic and incretin responses to, an oil/aqueous drink in type 2 diabetes mellitus
A Pilichiewicz et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus
T Vilsboll et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes
JJ Meier et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes
DJ Drucker
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2003)
Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs
CF Deacon et al.
JOURNAL OF ENDOCRINOLOGY (2002)
The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity
A Flint et al.
INTERNATIONAL JOURNAL OF OBESITY (2001)
Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide
CF Deacon et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2000)
Effects of glucagon-like peptide-1 (7-36) amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans
J Schirra et al.
GUT (2000)
分享论文
